Fmr LLC Cuts Stake in Humana Inc. (NYSE:HUM)

FMR LLC cut its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,254,141 shares of the insurance provider's stock after selling 134,718 shares during the period. FMR LLC owned about 2.70% of Humana worth $825,608,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. HighTower Advisors LLC raised its position in shares of Humana by 2.1% during the third quarter. HighTower Advisors LLC now owns 8,992 shares of the insurance provider's stock worth $2,852,000 after acquiring an additional 187 shares during the last quarter. IHT Wealth Management LLC increased its position in Humana by 38.2% during the 3rd quarter. IHT Wealth Management LLC now owns 1,082 shares of the insurance provider's stock valued at $334,000 after purchasing an additional 299 shares during the period. Stifel Financial Corp raised its holdings in Humana by 8.8% during the 3rd quarter. Stifel Financial Corp now owns 59,432 shares of the insurance provider's stock worth $18,825,000 after purchasing an additional 4,804 shares during the last quarter. Kovitz Investment Group Partners LLC lifted its position in shares of Humana by 61.6% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 4,179 shares of the insurance provider's stock worth $1,324,000 after purchasing an additional 1,593 shares during the period. Finally, Insigneo Advisory Services LLC boosted its stake in shares of Humana by 14.2% in the 3rd quarter. Insigneo Advisory Services LLC now owns 1,159 shares of the insurance provider's stock valued at $367,000 after purchasing an additional 144 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Remove Ads

Humana Stock Performance

Shares of HUM traded up $4.72 on Friday, reaching $294.97. 1,674,634 shares of the company's stock traded hands, compared to its average volume of 1,752,261. The stock's 50 day simple moving average is $265.55 and its two-hundred day simple moving average is $270.35. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The stock has a market cap of $35.60 billion, a PE ratio of 29.65, a PEG ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.20%. The ex-dividend date is Friday, March 28th. Humana's dividend payout ratio (DPR) is presently 35.58%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Barclays boosted their target price on shares of Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a report on Friday. JPMorgan Chase & Co. dropped their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Morgan Stanley decreased their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and issued a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Finally, Piper Sandler increased their price target on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. Seventeen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Humana has a consensus rating of "Hold" and a consensus target price of $288.60.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.